Actionable Mutations in NSCLC: Expert Perspectives in Testing and Targeted Therapy
EP. 1: Testing Approaches for Actionable Mutations in NSCLC in Clinical Practice
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.
EP. 2: Liquid Biopsies in the NSCLC Molecular Testing Algorithm
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.
EP. 3: Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.
EP. 4: Challenges Associated with Molecular Testing in NSCLC
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.
EP. 5: Updates in Treatment of NSCLC with Classical EGFR Mutations
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.
EP. 6: Recent Advances in Treatment of EGFR Exon 20 Insertion Mutations in NSCLC
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Dr Fernando Santini explains EGFR exon 20 insertion mutations in NSCLC and the best approaches for treating these cases.
EP. 7: Updates in Treatment of HER2 Mutant NSCLC
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Dr Misako Nagasaka reviews clinical trial data presented at ESMO 2021 on therapies for NSCLC harboring HER2 exon 20 mutations.
EP. 8: Recent Advances in Treatment of MET Exon 14 Skipping Mutations in NSCLC
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Dr Martin Dietrich provides an overview of how to treat MET exon 14 skipping mutations in non–small cell lung cancer.
EP. 9: Treatment of KRAS G12C Mutant NSCLC
ByMisako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Benjamin Levy, MD,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Benjamin Levy, MD, explains KRAS G12C mutations in non–small cell lung cancer, and Hatim Husain, MD, provides insight into the mechanism of action of G12C inhibitors.
EP. 10: Recent Advances in Treatment of NSCLC with NTRK Fusions
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Misako Nagasaka, MD, PhD, provides an overview of clinical trial data on treatments for NTRK fusion–positive lung cancer.
EP. 11: Treatment Selection and Sequencing for Patients with NTRK Fusions in Clinical Practice
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD A panel of lung cancer experts illustrate their personal clinical experience with treatment selection and sequencing for treating patients who have NTRK fusions.
Drs Fernando C. Santini and Hatim Hussain explain how they approach testing and treatment of patients with TRK fusion at diagnosis and progression in non–small cell lung cancer.
EP. 13: Updates in Treatment of NSCLC with ALK Rearrangements
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Oncologists review data from the ALTA-1L clinical trial and CROWN study on therapies for the treatment of ALK rearrangements.
EP. 14: Recent Advances in Treatment of ROS1-Rearranged NSCLC
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Hatim Hussain, MD, explains emerging data on ROS1 rearrangements in NSCLC and his approach to treatment in his clinical practice.
EP. 15: Emerging Antibody Drug Conjugates in the Lung Cancer Treatment Landscape
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Dr Martin Dietrich gives an overview of novel antibody-drug conjugates in the NSCLC treatment landscape.
EP. 16: Closing Expert Perspectives on Treatment in Advanced NSCLC
ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD Lung cancer experts share final thoughts on their thorough discussion of treatments in NSCLC and what to look for in the future.
